These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 38766114)

  • 1. Programable Albumin-Hitchhiking Nanobodies Enhance the Delivery of STING Agonists to Potentiate Cancer Immunotherapy.
    Wilson J; Kimmel B; Arora K; Chada N; Bharti V; Kwiatkowski A; Finklestein J; Hanna A; Arner E; Sheehy T; Pastora L; Yang J; Pagendarm H; Stone P; Taylor B; Hubert L; Gibson-Corley K; May J; McLean J; Rathmell J; Richmond A; Rathmell W; Balko J; Fingleton B; Hargrove-Wiley E
    Res Sq; 2024 May; ():. PubMed ID: 38766114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
    Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STING-Activating Polymer-Drug Conjugates for Cancer Immunotherapy.
    Sheehy TL; Kwiatkowski AJ; Arora K; Kimmel BR; Schulman JA; Gibson-Corley KN; Wilson JT
    ACS Cent Sci; 2024 Sep; 10(9):1765-1781. PubMed ID: 39345818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STING-Activating Polymer-Drug Conjugates for Cancer Immunotherapy.
    Sheehy TL; Kwiatkowski AJ; Arora K; Kimmel BR; Schulman JA; Gibson-Corley K; Wilson JT
    bioRxiv; 2024 Apr; ():. PubMed ID: 38585879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma.
    Wang-Bishop L; Wehbe M; Shae D; James J; Hacker BC; Garland K; Chistov PP; Rafat M; Balko JM; Wilson JT
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Delivery of STING Agonist via Albumin Nanoreactor Boosts Immunotherapeutic Efficacy against Aggressive Cancers.
    Miao Z; Song X; Xu A; Yao C; Li P; Li Y; Yang T; Shen G
    Pharmaceutics; 2024 Sep; 16(9):. PubMed ID: 39339252
    [No Abstract]   [Full Text] [Related]  

  • 7. Precisely Activating cGAS-STING Pathway with a Novel Peptide-Based Nanoagonist to Potentiate Immune Checkpoint Blockade Cancer Immunotherapy.
    Xing Y; Peng A; Yang J; Cheng Z; Yue Y; Liu F; Li F; Liu Y; Liu Q
    Adv Sci (Weinh); 2024 Apr; 11(15):e2309583. PubMed ID: 38233164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration.
    Wehbe M; Wang-Bishop L; Becker KW; Shae D; Baljon JJ; He X; Christov P; Boyd KL; Balko JM; Wilson JT
    J Control Release; 2021 Feb; 330():1118-1129. PubMed ID: 33189789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
    Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
    Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ionizable STING-Activating Nanoadjuvants Enhance Tumor Immunogenicity and Potentiate Immunotherapy Efficacy in Solid Tumors.
    Xian S; Chen X; Ren S; Chen X; Wang H
    Cancer Res; 2024 Sep; 84(18):3044-3057. PubMed ID: 38990727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses.
    Pulliam T; Jani S; Goff PH; Bhakuni R; Tabachnick-Cherny S; Smythe K; Seaton BW; Tachiki L; Kulikauskas R; Church C; Koelle DM; Nghiem P; Bhatia S
    J Immunother Cancer; 2024 Oct; 12(10):. PubMed ID: 39401968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
    Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
    J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-targeted delivery of a STING agonist improvescancer immunotherapy.
    Wu YT; Fang Y; Wei Q; Shi H; Tan H; Deng Y; Zeng Z; Qiu J; Chen C; Sun L; Chen ZJ
    Proc Natl Acad Sci U S A; 2022 Dec; 119(49):e2214278119. PubMed ID: 36442099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation.
    Du SS; Chen GW; Yang P; Chen YX; Hu Y; Zhao QQ; Zhang Y; Liu R; Zheng DX; Zhou J; Fan J; Zeng ZC
    Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1243-1255. PubMed ID: 34986380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A DNA-Modularized STING Agonist with Macrophage-Selectivity and Programmability for Enhanced Anti-Tumor Immunotherapy.
    Chen Y; Li R; Duan Q; Wu L; Li X; Luo A; Zhang Y; Zhao N; Cui K; Wu W; Liu T; Wan JB; Deng L; Li G; Hou L; Tan W; Xiao Z
    Adv Sci (Weinh); 2024 Aug; 11(32):e2400149. PubMed ID: 38898748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models.
    Berger G; Knelson EH; Jimenez-Macias JL; Nowicki MO; Han S; Panagioti E; Lizotte PH; Adu-Berchie K; Stafford A; Dimitrakakis N; Zhou L; Chiocca EA; Mooney DJ; Barbie DA; Lawler SE
    Proc Natl Acad Sci U S A; 2022 Jul; 119(28):e2111003119. PubMed ID: 35787058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy.
    Wang-Bishop L; Kimmel BR; Ngwa VM; Madden MZ; Baljon JJ; Florian DC; Hanna A; Pastora LE; Sheehy TL; Kwiatkowski AJ; Wehbe M; Wen X; Becker KW; Garland KM; Schulman JA; Shae D; Edwards D; Wolf MM; Delapp R; Christov PP; Beckermann KE; Balko JM; Rathmell WK; Rathmell JC; Chen J; Wilson JT
    Sci Immunol; 2023 May; 8(83):eadd1153. PubMed ID: 37146128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antagonism of regulatory ISGs enhances the anti-melanoma efficacy of STING agonists.
    Filderman JN; Taylor JL; Wang J; Zhang Y; Singh P; Ross MA; Watkins SC; Nedal Al Bzour A; Karapetyan L; Kalinski P; Storkus WJ
    Front Immunol; 2024; 15():1334769. PubMed ID: 38312842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration.
    Li K; Wang J; Zhang R; Zhou J; Espinoza B; Niu N; Wang J; Jurcak N; Rozich N; Osipov A; Henderson M; Funes V; Lyman M; Blair AB; Herbst B; He M; Yuan J; Trafton D; Yuan C; Wichroski M; Liu X; Fu J; Zheng L
    J Hematol Oncol; 2024 Aug; 17(1):62. PubMed ID: 39113096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation.
    Nakamura T; Sato T; Endo R; Sasaki S; Takahashi N; Sato Y; Hyodo M; Hayakawa Y; Harashima H
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34215690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.